Please go to the PowerPak homepage
and select a course.
Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology
Activity Description and Educational Objectives
In this activity, immuno-oncology (IO) and managed care experts review the rapidly evolving landscape of cancer immunotherapies and biomarkers, as well as the unique characteristics of this class of agents, assess benefits, risks, and costs of cancer immunotherapies and the shortcomings of current value models in that context, and provide guidance for how to optimally integrate these agents into treatment plans for patients with cancer in managed care settings.
Upon completion of this activity, participants will be able to:
- Discuss the rationale for cancer immunotherapy and mechanisms of action of different immunotherapeutic approaches
- Assess the efficacy and safety profiles of immunotherapies and immune-based combinations based on evidence from the latest clinical trials
- Describe the indications for and role of immunotherapies and combinations in the treatment of different cancers, and best practices for their integration into individualized treatment plans for patients
- Evaluate the latest research on value assessment of cancer immunotherapies and implications for decision-making in managed care settings
- Integrate immunotherapies into practice in managed care settings based on balanced assessments of benefits, risks, and costs, individual patient needs and preferences, and unique characteristics of cancer immunotherapies
This activity has been designed to meet the educational needs of managed care pharmacists, medical directors, payer physicians, nurse case managers, oncology nurses, and other clinicians involved in the management of patients with cancer.
Nursing Education Purpose Statement
The purpose of this activity is to improve knowledge and competence of nurses concerning the assessment of benefits, risks, and value of cancer immunotherapies.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
December 24, 2018
December 23, 2019
Time to Complete
Faculty and Disclosure/Conflict of Interest Policy
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CE/CPE activity during the past 12 months.
Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
William M. Scholl Professor and Vice-Chair Department of Oncology and Professor of Medicine
Georgetown University Medical Center
Washington, District of Columbia
Michael B. Atkins, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb and F. Hoffmann-La Roche Ltd/Genentech, Inc.
Advisory Board for Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Michael B. Atkins, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations and/or cancer immunotherapy biomarker testing platforms.
James T. Kenney, RPh, MBA
Manager, Specialty and Pharmacy Contracts
Harvard Pilgrim Health Care
James T. Kenney, RPh, MBA, has no financial interests/relationships or affiliations in relation to this activity.
James T. Kenney, RPh, MBA, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations and/or cancer immunotherapy biomarker testing platforms.
Matthew A. Goodman, MD
Matthew A. Goodman, MD, has no financial interests/relationships or affiliations in relation to this activity.
Bobbie Perrin, RN, OCN
Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.
Nancy Nesser, JD, PharmD
Nancy Nesser, JD, PharmD, has no financial interests/relationships or affiliations in relation to this activity.
Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education
Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.
The information provided at this CME/MOC/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Providership, Credit, and Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared with ABIM through the ACCME's Program and Activity Reporting System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hour(s).
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-18-017-H01-P.
This CME/MOC/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported through educational grants from Bristol-Myers Squibb and Merck & Co., Inc.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
About This CME/MOC/CE/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.
Copyright © 2000-2018, PeerView